Botulinum toxin treatment of secretory disorders
Identifieur interne : 003D93 ( Main/Exploration ); précédent : 003D92; suivant : 003D94Botulinum toxin treatment of secretory disorders
Auteurs : Markus Naumann [Allemagne] ; Wolfgang Jost [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Anti-Dyskinesia Agents (therapeutic use), Axilla (innervation), Bontoxilysin, Botulinum Toxins (therapeutic use), Hand (innervation), Humans, Hyperhidrosis (drug therapy), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson's disease, Salivary Gland Diseases (drug therapy), Sialorrhea (drug therapy), Treatment, botulinum toxin, focal hyperhidrosis, hyperlacrimation, sialorrhea.
- MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug therapy : Hyperhidrosis, Parkinson Disease, Salivary Gland Diseases, Sialorrhea.
- innervation : Axilla, Hand.
- Humans.
Abstract
Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long‐term benefits of this treatment option. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20067
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001D49
- to stream Istex, to step Curation: 001D49
- to stream Istex, to step Checkpoint: 002774
- to stream PubMed, to step Corpus: 003501
- to stream PubMed, to step Curation: 003501
- to stream PubMed, to step Checkpoint: 003541
- to stream Ncbi, to step Merge: 000D83
- to stream Ncbi, to step Curation: 000D83
- to stream Ncbi, to step Checkpoint: 000D83
- to stream Main, to step Merge: 005751
- to stream PascalFrancis, to step Corpus: 002237
- to stream PascalFrancis, to step Curation: 000A84
- to stream PascalFrancis, to step Checkpoint: 002225
- to stream Main, to step Merge: 005A63
- to stream Main, to step Curation: 003D93
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin treatment of secretory disorders</title><author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name></author><author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AD0354D854F1DAA714D12DA7382146966ECD7698</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20067</idno><idno type="url">https://api.istex.fr/document/AD0354D854F1DAA714D12DA7382146966ECD7698/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D49</idno><idno type="wicri:Area/Istex/Curation">001D49</idno><idno type="wicri:Area/Istex/Checkpoint">002774</idno><idno type="wicri:doubleKey">0885-3185:2004:Naumann M:botulinum:toxin:treatment</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15027066</idno><idno type="wicri:Area/PubMed/Corpus">003501</idno><idno type="wicri:Area/PubMed/Curation">003501</idno><idno type="wicri:Area/PubMed/Checkpoint">003541</idno><idno type="wicri:Area/Ncbi/Merge">000D83</idno><idno type="wicri:Area/Ncbi/Curation">000D83</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D83</idno><idno type="wicri:doubleKey">0885-3185:2004:Naumann M:botulinum:toxin:treatment</idno><idno type="wicri:Area/Main/Merge">005751</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0228841</idno><idno type="wicri:Area/PascalFrancis/Corpus">002237</idno><idno type="wicri:Area/PascalFrancis/Curation">000A84</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002225</idno><idno type="wicri:doubleKey">0885-3185:2004:Naumann M:botulinum:toxin:treatment</idno><idno type="wicri:Area/Main/Merge">005A63</idno><idno type="wicri:Area/Main/Curation">003D93</idno><idno type="wicri:Area/Main/Exploration">003D93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin treatment of secretory disorders</title><author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden</wicri:regionArea><wicri:noRegion>Wiesbaden</wicri:noRegion><wicri:noRegion>Wiesbaden</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S137">S137</biblScope><biblScope unit="page" to="S141">S141</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AD0354D854F1DAA714D12DA7382146966ECD7698</idno><idno type="DOI">10.1002/mds.20067</idno><idno type="ArticleID">MDS20067</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Axilla (innervation)</term><term>Bontoxilysin</term><term>Botulinum Toxins (therapeutic use)</term><term>Hand (innervation)</term><term>Humans</term><term>Hyperhidrosis (drug therapy)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Salivary Gland Diseases (drug therapy)</term><term>Sialorrhea (drug therapy)</term><term>Treatment</term><term>botulinum toxin</term><term>focal hyperhidrosis</term><term>hyperlacrimation</term><term>sialorrhea</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hyperhidrosis</term><term>Parkinson Disease</term><term>Salivary Gland Diseases</term><term>Sialorrhea</term></keywords><keywords scheme="MESH" qualifier="innervation" xml:lang="en"><term>Axilla</term><term>Hand</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Botulinum neurotoxin serotype A (BoNT/A) has revolutionised the treatment of a variety of autonomic hypersecretory disorders. Several open and controlled studies indicate that BoNT/A is a safe and effective treatment for focal hyperhidrosis of the axillae and palms, for gustatory sweating, and for some other rare conditions associated with focal hyperhidrosis. There is class I evidence for the efficacy of botulinum toxin in axillary hyperhidrosis and class II evidence for palmar hyperhidrosis and gustatory sweating. BoNT/A has the potential to replace current invasive and surgical techniques and should at least be considered as a viable alternative. The results of pilot studies to treat sialorrhea are encouraging. However, the optimal dose, best mode of application, side effects, and duration of BoNT/A action in this condition remain uncertain. We need further formal clinical trials to evaluate risks and benefits of BoNT/A for palliative treatment in of sialorrhea in Parkinson's disease and in bulbar amyotrophic lateral sclerosis. Based on the few reports published, BoNT/A injections into the lacrimal gland for hyperlacrimation may be an elegant method to treat this sometimes disabling condition. Again, larger studies are needed to evaluate the risks and long‐term benefits of this treatment option. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Basse-Franconie</li></region><settlement><li>Wurtzbourg</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name></region><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AD0354D854F1DAA714D12DA7382146966ECD7698
|texte= Botulinum toxin treatment of secretory disorders
}}
| This area was generated with Dilib version V0.6.23. |  |